

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
Alan Tan, MD	Faculty	1. Foundation Medicine, Natera 2. BMS, EMD Serono, Exelixis, Gilead, Merck, Myovant, Seagen/Astellas 3. Natera	1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Stock ownership interest in publicly held company	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Alexander Kutikov, MD, FACS	Faculty	No relevant financial disclosures	N/A	N/A
Anirban Kundu, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Andres Correa, MD	Faculty	No relevant financial disclosures	N/A	N/A
Ari Hakimi, MD	Faculty	1. AAA, Amgen, Astra Zeneca, Bayer, Bristol Myers Squibb, Genentech/Roche, Genome & Company, Incyte, Merck, Nektar, Peloton Therapeutics, Pfizer, SeaGen, Tricon Pharmaceuticals, Xencor	1. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Arpita Desai, MD	Faculty	1. Merck 2. Exelixis, Merck	1. Contract Research 2. Advisory Board	The following relationships ended: <ul style="list-style-type: none"> ▪ Exelixis: July 2023 ▪ Merck: July 2022 Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Benjamin Garmezy, MD	Faculty	<p>1. AbbVie, Accutar Biotechnology, Arcus Biosciences, Astra Zeneca, AVEO Oncology, CRISPR Therapeutics, Exelixis, Harbour BioMed, IDEAYA Biosciences, Janssen, JANUX Therapeutics, Jubilant Therapeutics, Kineta, Kinnate BioPharma, Loxo/Lilly, Mink Therapeutics, Nuvation Bio Inc, PROfound Bio, Roche Genentech, Teon Therapeutics, Xencor, Zenshine</p> <p>2. Amgen, Arvinas, Bayer, Merck, Pfizer, Sanofi/Aventis, SeaGen</p>	<p>1. Contract Research</p> <p>2. Non-CE Consulting</p>	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Amgen: ended prior to October 2023 ▪ Jubilant Therapeutics: ended prior to October 2023 ▪ Sanofi/Aventis: ended prior to October 2023 ▪ SeaGen: ended prior to October 2023 ▪ Teon Therapeutics: ended prior to October 2023 ▪ Zenshine: ended prior to October 2023 <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Ben Maughan, MD	Faculty	<p>1. AbbVie, Astellas, AVEO Oncology, Bayer Oncology, Bristol Myers Squibb, Clovis, Exelixis, Janssen, Lilly, Merck, Peloton Therapeutics, Pfizer, Sanofi, Telix, Tempus</p> <p>2. Bavarian-Nordic, Bristol Myers Squibb, Clovis, Exelixis</p>	<p>1. Consultant/Advisor</p> <p>2. Institutional funding for contract research</p>	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Bradley Leibovich, MD	Faculty	No relevant financial disclosures	N/A	N/A
Bradley McGregor, MD	Faculty	<p>1. Pfizer</p> <p>2. Pfizer</p>	<p>1. Contract Research</p> <p>2. Non-CE Consulting</p>	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Brian Rini, MD	Faculty	No relevant financial disclosures	N/A	N/A

Brian Shuch, MD	Faculty	1. Johnson & Johnson, Telix, Veracyte 2. Merck 3. UpToDate	1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Royalties	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Bruce Posner, PhD	Faculty	1. Rodeo Therapeutics, Corp	1. Intellectual property rights / patient holder, Royalties	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Chen Yao, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Christina Bargas, CMP	KCA Staff	No relevant financial disclosures	N/A	N/A
Daniel Geynisman, MD	Faculty, Planning Committee Member	1. Janssen, Merck	1. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted member of the planning committee. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Daniel George, MD	Faculty	1. Astra Zeneca, Astellas, Bayer, Exelixis, IDEOlogy Health, Janssen, Merck, Myovant, Pfizer, Propella, Rey Health, Sanofi 2. Astellas, Astra Zeneca, BMS, Calithera, Exelixis, Janssen, Novartis, Pfizer, Sanofi	1. Non-CE Consulting 2. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Daniel Shapiro, MD	Faculty	No relevant financial disclosures	N/A	N/A
Dean Elhag, MD	Faculty	No relevant financial disclosures	N/A	N/A
Dena Battle	Faculty	No relevant financial disclosures	NA	NA

Eric Jonasch, MD, MS	Faculty	1. Arrowhead Pharmaceuticals, Aveo, Corvus Pharmaceuticals, Merck, NiKang Therapeutics, Telix 2. Aveo, Eisai, Exelixis, Ipsen, Merck, NiKang Therapeutics, Novartis, Telix	1. Contract Research 2. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Eric Singer, MD, MA, MS, FACS, FASCO	Faculty	No relevant financial disclosures	N/A	N/A
Gretchen Vaughan, BBA	KCA Staff	No relevant financial disclosures	NA	NA
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	N/A	N/A
Hong Truong, MD	Faculty	No relevant financial disclosures	N/A	N/A
Ivan Pedrosa, MD, PhD	Faculty	1. Otsuka Pharmaceuticals	1. Advisory Board / Honoraria	The following relationships ended: <ul style="list-style-type: none"> Otsuka Pharmaceuticals: ended prior to October 2023
Jaleh Fallah, MD	Faculty	No relevant financial disclosures	N/A	N/A
Jeanette Stensgaard, MBA, CMP	KCA Staff	No relevant financial disclosures	NA	NA
Jodi Maranchie, MD	Faculty, Planning Committee Member	1. Janssen, Merck	1. Clinical trial support to institution	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted member of the planning committee. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jose Karam, MD, FACS	Faculty	1. Merck, Pfizer 2. Elypta, Merck, Mirati	1. Non-CE Consulting 2. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Kate Glennon, PhD Candidate	Faculty	No relevant financial disclosures	N/A	N/A
Kathy Liu	Faculty	No relevant financial disclosures	N/A	N/A
Katie Coleman	Faculty	No relevant financial disclosures	N/A	N/A
Katy Beckermann, MD, PhD	Faculty	1. Aravive, Aveo, Astra Zeneca, Alpine Bioscience, BMS, Exelixis, Merck, Sanofi, Seagen 2. BMS – IASLC – LCFA 3. Aravive, Arsenal Bio, Pionyr Immunotherapeutics	1. Non-CE Consulting 2. Institutional funding for contract research 3. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Kevin Kiernan	Faculty	No relevant financial disclosures	N/A	N/A
Kiran Virdee, RN, BSN, CCRN-K	Faculty, Planning Committee Member	No relevant financial disclosures	N/A	N/A
Kristen Brady	TFF Staff	No relevant financial disclosures	N/A	N/A
Laurence Albiges, MD, PhD	Faculty	1. Astellas, BMS, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, EISAI, Roche	1. Advisory or Consulting or Honoraria (all paid to institution)	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Mamta Parikh, MD, MS	Faculty	1. Bristol Myers Squibb, Myovant, Natera, Pfizer, Sanofi	1. Non-CE Consulting	The following relationships ended: <ul style="list-style-type: none"> ▪ Bristol Myers Squibb: December 2022 ▪ Myovant: June 2023 ▪ Natera: September 2022 ▪ Pfizer: June 2023 ▪ Sanofi: June 2023
Manojkumar Bupathi, MD, MS	Faculty	1. AAA, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech/Roche, Genome & Company, Incyte, Merck, Myovant, Nektar, Peloton Therapeutics, Pfizer, SeaGen, Tricon Pharmaceuticals, Xencor	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.

Maria Carlo, MD	Faculty, Planning Committee Member	No relevant financial disclosures	N/A	N/A
Maxine Sun, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Mehmet Asim Bilen, MD	Faculty	<ol style="list-style-type: none"> 1. AAA, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Genentech/Roche, Genome & Company, Merck, Nektar, Peloton Therapeutics, Pfizer, SeaGen, Tricon Pharmaceuticals, Xencor 2. AstraZeneca, Bayer, BMS, Calithera Biosciences, Eisai, EMD Serono, Exelixis, Genomic Health, Janssen, Nektar, Sanofi, SeaGen 	<ol style="list-style-type: none"> 1. Contract Research 2. Advisory Board 	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Mike Hurwitz, MD, PhD	Faculty	<ol style="list-style-type: none"> 1. Achilles Therapeutics, CRISPR Therapeutics, Iovance 2. Affini-T, CRISPR Therapeutics, Exelixis, Janssen, Pliant Therapeutics, Regeneron, TScan 	<ol style="list-style-type: none"> 1. Contract Research 2. Non-CE Consulting 	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Affini-T: June 2023 ▪ Exelixis: ended prior to October 2023 ▪ Janssen: ended prior to October 2023 ▪ Pliant Therapeutics: ended prior to October 2023 ▪ Regeneron: ended prior to October 2023 ▪ TScan: ended prior to October 2023 <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Mohammed Alghamdi, MD	Faculty	No relevant financial disclosures	N/A	N/A
Naomi Haas, MD	Faculty	1. Eisai, Roche Genentech	1. Non-CE Consulting	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Eisai: October 2022

		2. Exelixis, Merck & Co, Inc.	2. Contract Research	<ul style="list-style-type: none"> ▪ Roche Genentech: June 2022 <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Nizar M. Tannir, MD FACP	Faculty	<ol style="list-style-type: none"> 1. Arrowhead Pharmaceuticals, BMS, Calithera Biosciences, Exelixis, Nektar, Novartis 2. AstraZeneca: BMS, Eisai, Exelixis, Intellisphere, Merck Sharp & Dohme, Nektar, Neoleukin Therapeutics, Oncorena 	<ol style="list-style-type: none"> 1. Contract Research 2. Non-CE Consulting 	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Pavlos Msaouel, MD, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Peter Embi, MD, MS, FACP, FACMI, FAMIA, FIAHSI	Faculty	No relevant financial disclosures	N/A	N/A
Phillip Pierorazio, MD	Faculty, Planning Committee Member	<ol style="list-style-type: none"> 1. Wolters Kluwer, Health Publishing 2. American Urological Association (AUA) Practice Guidelines Committee 3. Ethicon, Site PI: OLYMPUS Trial 4. Testicular Cancer Awareness Foundation 5. Bristol Myers Squibb 	<ol style="list-style-type: none"> 1. Royalties 2. Funded systematic review with JH Evidence Based Practice Center 3. Scientific Advisory Board 4. Board of Directors 5. Consultant / Advisory Board 	<p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Pooja Ghatalia, MD	Faculty	1. Bristol Myers Squibb	1. Research grant to institution	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that</p>

		2. Merck, Oryzon	2. Funding to institution	it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Qing Zhang, PhD	Faculty	1. Exelixis	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Rahul Sheth, MD	Faculty	1. Boston Scientific, Replimune, Siemens, TriSalus Life Sciences	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Randy Sweis, MD	Faculty	1. AbbVie, Ascendis, Astellas, Astra Zeneca, BMS, CytomX, Eisai, EMD Serono, Genentech/Roche, Gilead, Immunocore, Lilly, Merck, Mirati Therapeutics, Moderna, Novartis, Pfizer, Pionyr Immunotherapeutics, Pyxis Oncology, QED Therapeutics, Scholar Rock, Seattle Genetics 2. AbbVie 3. Astellas, AstraZeneca, Aveo, BMS, Editas, Eisai, EMD Serono, Exelixis, Gilead, Janssen, Lilly, Mirati Therapeutics, Pfizer, Seattle Genetics, Silverback	1. Contract Research 2. Stock ownership interest in publicly held company 3. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Ritchie Johnson, MBA, BSN	Faculty	No relevant financial disclosures	N/A	N/A
Sally Dale	Faculty	No relevant financial disclosures	N/A	N/A
Salvatore La Rose	Faculty, KCA Staff	No relevant financial disclosures	N/A	N/A

Sandy Srinivas, MD	Faculty	No relevant financial disclosures	N/A	N/A
Sara Wobker, MD, MPH	Faculty	No relevant financial disclosures	N/A	N/A
Sarah Psutka, MD, MS	Faculty, Planning Committee Member	<ol style="list-style-type: none"> 1. Janssen 2. Merck 3. Bladder Cancer Advocacy Network, National Institute on Aging 4. Bladder Cancer, European Urology 5. Merck, ImmunityBio, Janssen 	<ol style="list-style-type: none"> 1. Contract Research 2. Non-CE Consulting 3. Research Funding 4. Editorial boards 5. Scientific Advisory Board 	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Merck: August 2021 ▪ ImmunityBio: prior to April 2023 <p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Shinji Ohtake, MD	Faculty	No relevant financial disclosures	N/A	N/A
Shivani Sud, MD	Faculty	No relevant financial disclosures	N/A	N/A
Simon Lo, MB, ChB, FACR, FASTRO	Faculty	No relevant financial disclosures	N/A	N/A
Sounak Gupta, MBBS, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Stephanie Berg, DO	Faculty, Planning Committee Member	<ol style="list-style-type: none"> 1. BMS, Eisai, Exelixis, Pfizer, Sanofi, SeaGen 2. BMS, Eisai, Exelixis 	<ol style="list-style-type: none"> 1. Consultant 2. Non-CE Speakers' Bureau 	<p>All consultant relationships ended in June 2023.</p> <p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Sumanta Pal, MD	Faculty	1. CRISPR Therapeutics, Ipsen	1. Travel support	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced,

				and is based on scientific evidence and/or clinical reasoning.
Theodore Bruno, MD, FACEHP	TFF Staff	No relevant financial disclosures	N/A	N/A
Tian Zhang, MD, MHS	Faculty, Planning Committee Member	<ol style="list-style-type: none"> 1. AstraZeneca, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Tempus 2. Aptitude Health, IntegrityCE, MJH Associates, PeerView, PlatformQ, Vaniam, WJ Weiser 3. Amgen, Aravive, AstraZeneca, Aveo, Bayer, BMS, Dendreon, Eisai, Eli Lilly, Exelixis, Janssen, Merck, Pfizer, Sanofi-Aventis, SeaGen 	<ol style="list-style-type: none"> 1. PI/Research Funding 2. Honoraria 3. Consultant 	<p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Vitaly Margulis	MD	No relevant financial disclosures	N/A	N/A
Vivek Narayan, MD, MSCE	Faculty	<ol style="list-style-type: none"> 1. Bristol Meyers Squibb, Exelixis, Janssen, Merck, Pfizer, Regeneron 	<ol style="list-style-type: none"> 1. Non-CE Consulting 	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Bristol Meyers Squibb: October 2022 ▪ Exelixis: October 2022 ▪ Janssen: February 2023 ▪ Merck: August 2022 ▪ Pfizer: March 2023 ▪ Regeneron: February 2023
Wayne Smith	Faculty	No relevant financial disclosures	N/A	N/A
Yasser Ged, MBBS	Faculty	<ol style="list-style-type: none"> 1. Eisai, Exelixis 	<ol style="list-style-type: none"> 1. Non-CE Consulting 	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Eisai: June 2023 ▪ Exelixis: November 2022
Yousef Zakharia, MD	Faculty, Planning Committee Member	<ol style="list-style-type: none"> 1. DSMC: Janssen Research and Development 2. Pfizer, Novartis 3. Institution clinical trial support from Pfizer, Exelixis, Eisai 	<ol style="list-style-type: none"> 1. Non-CE Consulting 2. Honoraria 3. Contract Research 	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Eisai: October 2022 ▪ Exelixis: 2022 ▪ Novartis: 2020 ▪ Seagen: 2022

		<p>4. Amgen, Array, AstraZeneca, Bayer, BMS, Castle Bioscience, Clovis, EMD Serono, Eisai, Exelixis, Genzyme Corporation, Janssen, Myovant, Novartis, Pfizer, Roche Diagnostics, Seagen</p>	<p>4. Advisory Board</p>	<p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
--	--	---	--------------------------	--